In yesterday’s Wall Street session, Taysha Gene Therapies Inc (NASDAQ:TSHA) shares traded at $3.10, up 4.73% from the previous session.
TSHA stock price is now 55.27% away from the 50-day moving average and 69.45% away from the 200-day moving average. The market capitalization of the company currently stands at $579.76M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $14 to $1.50, Jefferies Downgraded its rating from Buy to Hold for Taysha Gene Therapies Inc (NASDAQ: TSHA). On January 27, 2023, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock reducing its target price from $23 to quote $3, while ‘Goldman’ rates the stock as ‘Neutral’
In other news, Manning Paul B, 10% Owner bought 100,000 shares of the company’s stock on Nov 17 ’23. The stock was bought for $163,000 at an average price of $1.63. Upon completion of the transaction, the 10% Owner now directly owns 16,566,667 shares in the company, valued at $51.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 24 ’23, Chief Financial Officer Alam Kamran sold 33,000 shares of the business’s stock. A total of $76,890 was realized by selling the stock at an average price of $2.33. This leaves the insider owning 258,042 shares of the company worth $0.8 million. A total of 31.24% of the company’s stock is owned by insiders.
During the past 12 months, Taysha Gene Therapies Inc has had a low of $0.50 and a high of $3.89. As of last week, the company has a debt-to-equity ratio of 0.82, a current ratio of 4.06, and a quick ratio of 4.06. The fifty day moving average price for TSHA is $2.0201 and a two-hundred day moving average price translates $1.8408 for the stock.
The latest earnings results from Taysha Gene Therapies Inc (NASDAQ: TSHA) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0.92, beating analysts’ expectations of -$0.11 by 1.03. This compares to -$0.96 EPS in the same period last year. The net profit margin was -722.06% and return on equity was -294.04% for TSHA. For the current quarter, analysts expect TSHA to generate $1.49M in revenue.
